Skip navigation
  • 中文
  • English

DSpace CRIS

  • DSpace logo
  • Home
  • Organizations
  • Researchers
  • Research Outputs
  • Explore by
    • Organizations
    • Researchers
    • Research Outputs
  • Academic & Publications
  • Sign in
  • 中文
  • English
  1. NTU Scholars
  2. 醫學院
  3. 醫學系
Please use this identifier to cite or link to this item: https://scholars.lib.ntu.edu.tw/handle/123456789/526456
Title: Improved treatment results for childhood acute myeloid leukemia in Taiwan
Authors: Liang D.-C.
Chang T.-T.
Lin K.-H.
Lin D.-T.
MENG-YAO LU 
Chen S.-H.
Liu H.-C.
Lin M.-T.
Lee M.-T.
Shu S.-G.
Chang T.-K.
Chen J.-S.
Hsiao C.-C.
Hung I.-J.
Hsieh Y.-L.
Chen R.-L.
Cheng S.-N.
Chang W.-H.
Lee C.-H.
Lin K.-S.
Keywords: Childhood acute myeloid leukemia; Outcome; Treatment
Issue Date: 2006
Publisher: Nature Publishing Group
Journal Volume: 20
Journal Issue: 1
Start page/Pages: 136-141
Source: Leukemia
Abstract: 
To improve treatment results for children with de novo acute myeloid leukemia (AML), we introduced a novel protocol, Taiwan Pediatric Oncology Group-AML-97A, for AML other than acute promyelocytic leukemia (APL), for which modified conventional protocols were used. From January 1, 1997, to December 31, 2002, 141 children younger than 17 years old with de novo AML were enrolled. In total, 117 patients with non-APL AML were treated with induction therapy of idarubicin and cytarabine (Ara-C), postremission therapy with high-dose Ara-C - containing regimens for four monthly courses, and moderate-dose therapy with idarubicin and Ara-C for four monthly courses. The first 19 patients with APL were treated with all-trans retinoic acid, idarubicin and Ara-C, with the remaining five patients receiving all-trans retinoic acid and idarubicin, followed by maintenance therapy for 2 years. Stem cell transplantation was performed in 29 patients in first remission with a similar outcome as chemotherapy alone. The remission rate in the AML-97A study was 90%, the 5-year survival 51±5.3% (s.e.) and the 5-year event-free survival 50±4.8%; for APL, these were 100%, 86±7.0, and 75±9.8%. For the whole group, the 5-year survival was 57±4.7% and the 5-year event-free survival 54±4.4%. The AML-97A regimen was well tolerated. ? 2006 Nature Publishing Group All rights reserved.
URI: https://www.scopus.com/inward/record.uri?eid=2-s2.0-33644988994&doi=10.1038%2fsj.leu.2403979&partnerID=40&md5=09874d2bcdc8a52bb90f103fde79ebec
https://scholars.lib.ntu.edu.tw/handle/123456789/526456
ISSN: 0887-6924
DOI: 10.1038/sj.leu.2403979
SDG/Keyword: cotrimoxazole; cytarabine; etoposide; granulocyte colony stimulating factor; idarubicin; methotrexate; mitoxantrone; rasburicase; retinoic acid; acute granulocytic leukemia; adolescent; article; bleeding; cancer regression; cancer survival; cardiotoxicity; child; childhood leukemia; clinical protocol; clinical trial; drug dose regimen; drug megadose; drug tolerability; febrile neutropenia; human; infection; intermethod comparison; meta analysis; outcome assessment; Pneumocystis pneumonia; priority journal; promyelocytic leukemia; sepsis; stem cell transplantation; Taiwan; tumor lysis syndrome
[SDGs]SDG3
Appears in Collections:醫學系

Show full item record

SCOPUSTM   
Citations

35
checked on May 23, 2023

WEB OF SCIENCETM
Citations

32
checked on May 24, 2023

Page view(s)

22
checked on May 30, 2023

Google ScholarTM

Check

Altmetric

Altmetric

Related Items in TAIR


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Sherpa Romeo網站查詢,以確認出版單位之版權政策。
    Please use Sherpa Romeo to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)
Build with DSpace-CRIS - Extension maintained and optimized by Logo 4SCIENCE Feedback